HIV infection prevents myelin-associated oligodendrocytes from maturing, this, in turn, hampers white matter production in the brain.
Lower serum levels of the sugar metabolite GlcNAc was associated with progressive disability and neurodegeneration in patients with multiple sclerosis.
Researchers shed new light on how remylination fails in multiple sclerosis. The study reports a drug, currently being studied as a cancer therapy, can alter the key signaling cascades that result in demylination associated with MS.
Cells that drive myelin repair become less efficient due to aging. Myelin loss results in cognitive decline and is central to a number of neurodegenerative diseases.
A newly developed hydrogel scaffold with regularly spaced pores assists in spinal cell growth and neuron regeneration following spinal cord injury.
Some of the T cell epitopes targeting myelin in monkeys were the same as those found in humans. Researchers say linking these specific cells opens the doors to developing antiviral therapies that could be useful to treat newly diagnosed cases of MS in humans.
A newly engineered compound prevents damage to myelin and nerve fibers by stimulating a protective response in cells that produce and maintain myelin. The compound has positive implications for the treatment of Multiple Sclerosis.
Researchers have discovered a two-pronged approach to restore myelin on regenerated axons in a mouse model of optic nerve damage. The findings have positive implications for the treatment of multiple sclerosis.
N-acetylglucosamine, a simple sugar found in breast milk, promotes remyelination in mouse models of multiple sclerosis. The findings could have implications for treating multiple sclerosis in humans.
eEF1a1 activated by acetylation prevents remyelination, but if the protein is deactivated by deacetylation, myelin sheaths can be rebuilt. The findings shed light on the process of remyelination and could provide avenues of treatment for multiple sclerosis, and other conditions associated with demyelination.